Table 1 HERV loci colocalise with diffpeaks, indicating increased acetylation after HDACi treatment.

From: Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors

HERV loci info

diffpeak Log10 (p-value)

Chr

Start

End

Strand

ID

Group

Vorinostat

Romidepsin

19

53044740

53051680

+

ERV-V2

ERVV

5.32

8.78

19

5548587

5553253

+

4594

HERVH

5.98

1

117815373

117821863

6028

HERVS

3.94

5.51

14

92622417

92629608

4215

HERVIP

4.41

11

121632566

121643491

3656

HERVH

4.27

3.17

5

10716252

10725049

+

1756

HERVL

3.85

2

100361988

100365940

2q11.2

HML8

3.52

3.70

4

20194383

20199906

+

1335

HERVH

3.59

3

94647178

94651193

+

3q11.2

HML7

3.50

19

21786150

21792221

19p12b

HML6

3.09

3.34

1

185578774

185596328

6125

HML5

3.10

  1. Differential peak (diffpeak) p-values are depicted as the mean of two independent CHIP-seq experiments.